Use of RIT-Seq to Decode Antitrypanosomal Drug Efficacy and Resistance
Alsford, Eckert et al., Nature
A team led by investigators at the London School of Hygiene and Tropical Medicine this week reports its use of all five current human African trypanosomiasis drugs in a genome-scale RNA interference target sequencing screen in Trypanosoma brucei, which it says revealed the "transporters, organelles, enzymes and metabolic pathways that function to facilitate antitrypanosomal drug action." Taking this RIT-seq profiling approach, the team identified "both known drug importers and the only known pro-drug activator, and [linked] more than fifty additional genes to drug action," it writes.
Illumina Postpones Earnings Report as it Considers Roche's $5.7B Hostile Takeover Bid
January 27, 2012
Roche's Bid for Illumina Likely to Increase, Other Suitors May Emerge, Analysts Say
January 26, 2012
Illumina Will Weigh Roche's $5.7B Hostile Takeover Bid; Asks Shareholders to "Take No Action" Yet
January 25, 2012
CSHL-Led Team Develops De Novo Genome Assembly Method with Error-Corrected PacBio Reads
January 24, 2012
Complete Genomics Publishes Analysis Method, Plans Improvements to Enable Haplotyping
January 24, 2012